After one false alarm, Rigel Pharmaceuticals has officially won FDA approval for its lead rare disease therapy, Tavalisse.

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.

It’s been a strange road for BMS' Opdivo-Yervoy combo in first-line kidney cancer, but the New Jersey drugmaker finally has a go-ahead.

While consumers are all abuzz about the Facebook data scandal, pharma companies don't need to scramble. Just keep an eye open.

​​​​​​​Thermo Fisher features its employees and the patients they help in a new campaign that personalizes its drug development and delivery services.

Merck has put up some monster Keytruda-chemo combo numbers that'll raise the bar for rivals looking to steal the class crown.

In February, BMS tallied a lung cancer win for its immuno-oncology combo. But one question remained: Was the win big enough to keep it competitive?